UDI and AusUDID: Four Mandatory Dates, Scope Exemptions and the Relabelling Trap

1. Key takeaways

The Australian UDI regime was written into the Therapeutic Goods (Medical Devices) Regulations 2002 by F2025L00414 (March 2025), with the obligation clauses located in Essential Principles clauses 13.5, 13.6, 13A.2 and 13C.1–13C.5. There are four mandatory compliance dates: 1 July 2026, 2027, 2028 and 2029. Class I devices and Class Im (measuring) devices fall entirely outside the scope; for Class 1 IVDs only instruments (CT943) and software (CT944) are within scope. The staged dates give lower-risk classes a longer runway, but the relabelling trigger can pull an individual product into scope earlier than its class date alone would suggest.

2. Legal basis

The UDI obligations attach through the Essential Principles, which means non-compliance is assessed on the same footing as any other breach of that Schedule. The key instruments, clauses and dates are set out below. The clauses operate cumulatively: identifiers must be issued by an accredited agency, submitted to the database, kept accurate, and in specified cases directly marked on the device itself. Sponsors should therefore map each product against all of the applicable clauses rather than treating the database submission as the end of the task.

1. Legislative instrument: Therapeutic Goods Legislation Amendment (Australian Unique Device Identification Database and Other Measures) Regulations 2025, registered as F2025L00414, in force March 2025.
2. Essential Principles clauses: 13.5 (UDI-DI and UDI-PI provided with the device); 13.6 (packaging labelling); 13A.2 (patient implant card); 13C.1 (identifiers issued by an accredited issuing agency); 13C.2 (identifiers included in AusUDID); 13C.3 (other device-related data included in AusUDID); 13C.4 (information accurate and up to date); 13C.5 (UDI-DI/PI directly marked on the device itself).
3. Four mandatory compliance dates (TGA decision tree, When does UDI apply to my device, 26 September 2025): Class III — 1 July 2026; Class IIb — 1 July 2026; Class IIa — 1 July 2027; Class Is — 1 July 2028; Class 4 IVD — 1 July 2028; Class 3 IVD — 1 July 2028; Class 2 IVD — 1 July 2029; Class 1 IVD (instruments CT943 and software CT944 only) — 1 July 2029.
4. Scope exclusion: Class I and Class Im devices are not within the UDI scope.
5. “Legacy device” backstop: devices manufactured before their compliance start date and still under the sponsor’s control on 1 July 2029 must comply from that date; relabelling after the compliance date triggers the UDI obligations (exemptions from direct marking are unaffected).
6. EU transition pathways: implantable Class IIb (MDD→MDR) — 1 January 2028; non-implantable Class IIb and similar — 1 January 2029; Class 3 IVD (IVDD→IVDR) — 1 January 2029 / 1 January 2030; direct marking under the respective pathways — 1 January 2028, 1 January 2029, 1 July 2029 and 1 July 2030.
7. Purpose of AusUDID: to give patients, consumers and health professionals consistent and convenient access to device information; it is not intended for inventory or stock tracking (any such benefit is secondary only).
8. Transition channel: the TGA consulted on the UDI Consent to Supply process and fees (opened 10 December 2025, closed 23 January 2026), allowing a 2-year period of non-compliance that cannot be extended; the UDI-specific consent fee for 2026–27 was reduced to AUD 80 plus AUD 10 for each additional entry (Cost Recovery Implementation Statement 2026-27).
9. Consequences: suspension or cancellation of the ARTG entry, civil penalties under Part 4-11, Division 1 of the Therapeutic Goods Act 1989, and infringement notices.

3. Expert insights

Insight 1: UDI non-compliance is a breach of the Essential Principles. The obligations were written into the Essential Principles themselves, and the consequences run directly to suspension or cancellation of the entry. This determines that a UDI project must be led by the regulatory affairs team, not by IT or packaging. That framing also explains the severity of the consequences: a data field that is out of date is not a housekeeping defect to be corrected at leisure, but a non-compliance that feeds directly into the enforcement consequences described in article 47. The clauses leave little room for proportionality arguments, which is another reason to front-load the compliance work.

Insight 2: relabelling immediately triggers the UDI obligations. After the compliance date, changing even a single label element moves the entire product into UDI scope. Companies planning packaging upgrades, multilingual versions or brand refreshes must assess the UDI impact at the same time. A label change signed off without that assessment is a compliance exposure discovered at the worst possible moment.

Insight 3: the UDI consent is a low-cost transition channel, but it is capped at 2 years and cannot be extended. The fee has been reduced to AUD 80 at the entry level, but the consent is valid for 2 years, and on expiry a new application must be made rather than an extension sought. It works as a buffer; it does not work as a long-term strategy.

4. Practical recommendations

• Plan backwards from the four dates: treat 1 July 2026 for Class III and Class IIb as the first milestone, and prioritise labelling, packaging, UDI-DI assignment and AusUDID submission — the four workstreams that consume the most calendar time.
• Establish a labelling change review process, with a UDI trigger assessment carried out before any label revision.
• For products that cannot comply on time, apply early for the UDI-specific consent (from AUD 80) and complete remediation within the 2-year window.
• Carry the UDI consistently in adverse event reports and recall notices — this is the implied linkage requirement of the Essential Principles.

5. Verification checklist

• □ The applicable mandatory tier (2026 / 2027 / 2028 / 2029) has been confirmed for each device class
• □ It has been confirmed whether Class I and Class Im devices are in or out of scope
• □ UDI-DIs have been issued by an accredited issuing agency and submitted to AusUDID
• □ A UDI trigger review process for labelling changes has been established
• □ The UDI-specific consent has been assessed for products that cannot comply on time

Regulatory information verified as of 29 October 2026.

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support for the Australian market. Our team manages adverse event reporting and recall coordination with the TGA, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com